Product Description: ERK2/p38α MAPK-IN-1 (Compound 1, In silico Hit-2) is a potent and selective ERK2 and p38α MAPK inhibitor, with an IC50 of 82 μM for ERK2. ERK2/p38α MAPK-IN-1 binds to the allosteric site of ERK2 and p38α MAPK in distinct manners. ERK2/p38α MAPK-IN-1 can be used for the research of type 2 diabetes[1].
Formula: C20H16FN3O4S2
References: [1]Hasegawa S, et al. Distinct binding modes of a benzothiazole derivative confer structural bases for increasing ERK2 or p38α MAPK selectivity. Biochem Biophys Res Commun. 2024 Apr 16;704:149707./[2]Kinoshita T, et al. Identification of allosteric ERK2 inhibitors through in silico biased screening and competitive binding assay. Bioorg Med Chem Lett. 2016 Feb 1;26(3):955-958.
CAS Number: 1016427-72-7
Molecular Weight: 445.49
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: ERK;p38 MAPK